IDXG - ピ―ディ―アイ (Interpace Diagnostics Group Inc.)

IDXGのニュース

   Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020  2020/06/24 20:20:00 GlobeNewswire
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial…
   Stock Alert: Interpace Biosciences Stock Up 20% In Premarket  2020/04/27 08:38:00 RTT News
Shares of Interpace Biosciences Inc. (IDXG) are up 20% in pre-market today, after the company announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company with more than 3 million members, focused on laboratory testing.
   Interpace Biosciences CEO Jack Stover On Diagnostics Business: 'Much Of The Growth Opportunity Is Around Awareness'  2020/04/01 20:26:10 Benzinga
Interpace Biosciences (NASDAQ: IDXG ) provides complex molecular analysis for the early diagnosis and treatment of cancer. The company also supports the development of targeted therapeutics. Benzinga interviewed Jack Stover, Interpace's president and CEO, about the business. Benzinga: One of Interpace's business partnerships is with Genecast Biotechnology in China. Can you give some insight into this partnership? Stover: Genecast is associated with our biopharma business. They also provide clinical trial services to Chinese companies looking for drug approval. Interpace will be bringing to them U.S. pharmaceutical companies that need a Chinese clinical component for their trials, while Genecast will be bringing to us Chinese companies that need a U.S. clinical component to their trials. So this is a first step for us in international expansion, along with a few others in Western Europe. Benzinga: What is Interpace's approach to expand in the molecular testing sector? Stover: Our core business is broken into two pieces, both around a molecular diagnostic environment.
   Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners - NetworkNewsWire  2020/01/23 18:45:44 NetworkNewsWire
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies Life sciences industry forecast to reach … Continue reading "Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners"
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020  2020/06/24 20:20:00 GlobeNewswire
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial…
   Stock Alert: Interpace Biosciences Stock Up 20% In Premarket  2020/04/27 08:38:00 RTT News
Shares of Interpace Biosciences Inc. (IDXG) are up 20% in pre-market today, after the company announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company with more than 3 million members, focused on laboratory testing.
   Interpace Biosciences CEO Jack Stover On Diagnostics Business: 'Much Of The Growth Opportunity Is Around Awareness'  2020/04/01 20:26:10 Benzinga
Interpace Biosciences (NASDAQ: IDXG ) provides complex molecular analysis for the early diagnosis and treatment of cancer. The company also supports the development of targeted therapeutics. Benzinga interviewed Jack Stover, Interpace's president and CEO, about the business. Benzinga: One of Interpace's business partnerships is with Genecast Biotechnology in China. Can you give some insight into this partnership? Stover: Genecast is associated with our biopharma business. They also provide clinical trial services to Chinese companies looking for drug approval. Interpace will be bringing to them U.S. pharmaceutical companies that need a Chinese clinical component for their trials, while Genecast will be bringing to us Chinese companies that need a U.S. clinical component to their trials. So this is a first step for us in international expansion, along with a few others in Western Europe. Benzinga: What is Interpace's approach to expand in the molecular testing sector? Stover: Our core business is broken into two pieces, both around a molecular diagnostic environment.
   Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners - NetworkNewsWire  2020/01/23 18:45:44 NetworkNewsWire
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies Life sciences industry forecast to reach … Continue reading "Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners"
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020  2020/06/24 20:20:00 GlobeNewswire
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial…
   Stock Alert: Interpace Biosciences Stock Up 20% In Premarket  2020/04/27 08:38:00 RTT News
Shares of Interpace Biosciences Inc. (IDXG) are up 20% in pre-market today, after the company announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company with more than 3 million members, focused on laboratory testing.
   Interpace Biosciences CEO Jack Stover On Diagnostics Business: 'Much Of The Growth Opportunity Is Around Awareness'  2020/04/01 20:26:10 Benzinga
Interpace Biosciences (NASDAQ: IDXG ) provides complex molecular analysis for the early diagnosis and treatment of cancer. The company also supports the development of targeted therapeutics. Benzinga interviewed Jack Stover, Interpace's president and CEO, about the business. Benzinga: One of Interpace's business partnerships is with Genecast Biotechnology in China. Can you give some insight into this partnership? Stover: Genecast is associated with our biopharma business. They also provide clinical trial services to Chinese companies looking for drug approval. Interpace will be bringing to them U.S. pharmaceutical companies that need a Chinese clinical component for their trials, while Genecast will be bringing to us Chinese companies that need a U.S. clinical component to their trials. So this is a first step for us in international expansion, along with a few others in Western Europe. Benzinga: What is Interpace's approach to expand in the molecular testing sector? Stover: Our core business is broken into two pieces, both around a molecular diagnostic environment.
   Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners - NetworkNewsWire  2020/01/23 18:45:44 NetworkNewsWire
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies Life sciences industry forecast to reach … Continue reading "Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners"
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.

calendar